Table 2 Univariate evaluation of risk factors for development of thrombocytopenia
From: Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients
Episodes with thrombocytopenia, n = 48 (40.7%) | Episodes without thrombocytopenia, n = 70 (59.3%) | P-value | |
|---|---|---|---|
Demographics | |||
Age (years), median (IQR) | 72 (66–77.8) | 69 (49.5–78) | 0.28 |
Sex (male/female), (%/%) | 32/16 (66.7/33.3) | 44/26 (62.9/37.1) | 0.70 |
Height (m), median (IQR) | 1.60 (1.51–1.67) | 1.63 (1.54–1.68) | 0.18 |
Body weight (kg), median (IQR) | 51.5 (45.4–60.2) | 60.0 (53.3–65.1) | 0.0048 |
Body mass index (kg/m2), median (IQR) | 21.1 (19.1–23.3) | 22.5 (20.7–25.3) | 0.0082 |
Laboratory, median (IQR) | |||
Serum creatinine (mg/dL) | 0.80 (0.52–1.26) | 0.60 (0.50–0.83) | 0.040 |
CLCRC-G ≤ 60 mL/min | 22 (45.8) | 13 (18.6) | 0.0020 |
Total bilirubin (mg/dL) | 0.4 (0.3–0.6) | 0.5 (0.3–0.73) | 0.43 |
Baseline haematological parameters, median (IQR) | |||
Hemoglobin concentration (g/dL), median (IQR) | 9.3 (8.4–10.5) | 10.0 (8.7–11.8) | 0.033 |
Platelet count (×103/μL), median (IQR) | 205 (143.5–254.5) | 303.5 (195–382.5) | < 0.0001 |
Low platelet count at baseline < 150 × 103/μL, n (%) | 13 (27.1) | 10 (14.3) | 0.101 |
Episodes with platelet transfusion during therapy, n (%) | 6 (12.5) | 2 (2.9) | 0.061 |
Episodes with DIC, n (%) | 9 (18.8) | 6 (8.6) | 0.16 |
Main reason for linezolid | |||
Type of infection, n (%) | |||
Skin and soft tissue infections, and surgical site infections | 17 (35.4) | 30 (42.9) | 0.45 |
Bacteraemia | 19 (39.6) | 17 (24.3) | 0.103 |
Bone and joint infections | 13 (27.1) | 18 (25.7) | 1.00 |
Respiratory tract infections | 9 (18.8) | 17 (24.3) | 0.51 |
Intra-abdominal infections | 3 (6.3) | 5 (7.1) | 1.00 |
Mediastinitis | 4 (8.3) | 3 (4.3) | 0.44 |
Central nervous system infections | 0 (0.0) | 5 (7.1) | 0.079 |
Endocarditis | 2 (4.2) | 2 (2.9) | 1.00 |
Urinary tract infections | 2 (4.2) | 2 (2.9) | 1.00 |
Unknown | 3 (6.3) | 3 (4.3) | 0.69 |
Linezolid dosage and exposure | |||
Empirical/target therapy, n/n (%/%) | 6/48 (12.5/87.5) | 11/59 (15.7/84.3) | 0.79 |
Mean Cmin of fixed doses in steady state (mg/L), mean ± SD | 20.6 ± 10.8 | 15.3 ± 9.8 | 0.0023 |
Duration of linezolid treatment (days), median (IQR) | 21 (12–42.8) | 19.5 (10.8–34.3) | 0.29 |